logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
19/06/2025
Federal Reserve Chairman Powell: Today we discussed at a high level improving communication, including modifications to the "Economic Forecast Summary." We will discuss in more detail changes to communication methods in the fall.
Latest
2 m ago
Shell CEO: The oil market is currently in a balanced state.
2 m ago
Shell CEO: The oil market is currently in a balanced state.
3 m ago
Zhuhai Airport has an annual passenger throughput of nearly 13 million.
3 m ago
Each SmartAI News, Great Wall Guorui Securities released a research report on June 18th, giving a buy rating to the First Medicine Holdings (688197.SH). The rating reasons mainly include: 1) focusing on the innovative small molecule drugs for NSCLC, and also having second-generation and third-generation ALK-TKIs; 2) the commercial value of the second-generation ALK-TKI is about to be released, and the clinical progress of the third-generation ALK-TKI is smooth; 3) the Chinese ALK-TKI market: the second-generation is dominant, and the differentiated competitive landscape is emerging; 4) SY-5007: a domestically produced selective RET-TKI with advanced research and development progress, in Phase III clinical follow-up. (Daily Economic News)
4 m ago
Eiji Hashimoto, CEO of Nippon Steel, said: "We have proposed the golden share plan."
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.